ArticleJournal of cancer research and clinical oncology2026
Regression of high-grade squamous intraepithelial lesions in women aged 30 years or younger: a retrospective cohort study.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the rate and timing of spontaneous regression of high-grade cervical intraepithelial lesions (CIN2/HSIL and CIN3/HSIL) in young women and to identify associated factors.
methodsThis retrospective cohort study included patients aged ≤ 30 years diagnosed with HSIL (CIN2 or CIN3) at the certified dysplasia unit of the Department of Gynecology, University Hospital Erlangen, between April 2014 and November 2025 who underwent observational management. Regression was defined as partial regression (low-grade squamous intraepithelial lesion; LSIL) or complete regression (less than LSIL), with histology as the reference standard.
results45 patients with CIN3/HSIL and 38 with CIN2/HSIL were included. In the CIN3/HSIL cohort, regression was observed in 21 of 45 patients (46.7%), including regression to LSIL in 6 (13.3%) and complete regression in 15 (33.3%) cases. The median time to regression (≤ LSIL) was 236 days (IQR, 126-308 days). The CIN2/HSIL cohort showed even higher regression rates, with partial or complete regression in 24 of 38 cases (63.2%). Regression was associated with HPV clearance in both groups and with HPV16 negativity and HPV vaccination in the CIN2/HSIL cohort. No cases of progression to (micro)invasive disease were observed in either group. The probability of regression did not differ between patients aged ≤ 24 and > 24 years.
conclusionIn this selected cohort of women aged ≤ 30 years managed conservatively, spontaneous regression of CIN2/HSIL and CIN3/HSIL occurred frequently, particularly during the first year of follow-up, without progression to invasive disease. HPV clearance, HPV16 and vaccination status may help guide patient selection for observational management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.